Cellectar Biosciences (CLRB) Cash & Equivalents (2010 - 2026)

Cellectar Biosciences has reported Cash & Equivalents for 16 years, with the latest figure at $13.2 million in Q4 2025.

• Quarterly Cash & Equivalents fell 43.34% year-over-year to $13.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $13.2 million (down 43.34% YoY) and the FY2025 annual result came in at $13.2 million, down 43.34% from the prior year.
• Cash & Equivalents grew to $13.2 million in Q4 2025 per CLRB's latest filing, from $12.6 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $53.6 million in Q1 2021 and troughed at $5.2 million in Q2 2023.
• A 5-year average of $24.5 million and a median of $21.6 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2021 and 2023: Cash & Equivalents soared 656.15% in 2021, then sank 79.23% in 2023.
• Over 5 years, Cash & Equivalents stood at $35.7 million in 2021, then sank by 44.36% to $19.9 million in 2022, then tumbled by 51.85% to $9.6 million in 2023, then surged by 143.48% to $23.3 million in 2024, then plunged by 43.34% to $13.2 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $13.2 million, $12.6 million, and $11.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.